Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Novavax, Inc. announced an agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to secure an initial 3.2 million doses of Novavax' ...
read more
Novavax, Inc. announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the FDA to provide a two-dose primary series for active ...
read more
Valneva announced that the European Commission (EC) approved an amendment to the Advance Purchase Agreement (APA) signed in November 2021 for Valneva’s inactivated whole-virus COVID-19 vaccine, ...
read more
The Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for primary immunization to prevent...
read more
Pfizer and BioNTech initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine ...
read more
SARS-CoV-2, the virus responsible for the global COVID-19 pandemic, has caused millions of infections and more than five million deaths worldwide to date. Although the speed with which COVID-19 ...
read more
The events of the past two years have made a profound impact on biopharmaceutical companies and every cog in the wheel of our industry. Internally, firms were forced to make radical shifts in ...
read more
Novavax announced the initiation of its Phase 2b/3 Hummingbird™ clinical trial. The trial will evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax
read more
Novavax announced that it submitted an application to the FDA for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent coronavirus ...
read more
Merck and Orna Therapeutics are collaborating to discover, develop, and commercialize multiple drug modalities, including vaccines and therapeutics in the areas of infectious disease and oncology.
read more
Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received expanded emergency use authorization (EUA) from the FDA to provide a two-dose primary series for active ...
read more
Ascletis Pharma announced that the China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting ...
read more
Wednesday, August 24, 2022
Pfizer and BioNTech updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing...
read more
Wednesday, August 24, 2022
Valneva confirmed that the World Health Organization (WHO) issued recommendations for use of the their inactivated COVID-19 vaccine.
read more
Pfizer and BioNTech completed a submission to the European Medicines Agency (EMA) for the booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and ...
read more